Table 1.
Demographics and outcomes at baseline and after 12 weeks of treatment
| Baseline values | Values after 12 weeks of treatment | |||||
|---|---|---|---|---|---|---|
| Total population n = 84 | Patients in self-perceived remission at week 12, n = 45 | Patients not in self-perceived remission at week 12, n = 39 | Total population, n = 84 | Patients in self-perceived remission at week 12, n = 45 | Patients not in self-perceived remission at week 12, n = 39 | |
| Demographics | ||||||
| Gender (female), n (%) | 56 (66.7) | 31 (69.9) | 25 (64.1) | |||
| Age (years) | 50.0 (12.4) | 50.4 (13.2) | 49.4 (11.5) | |||
| RF positive, n (%) | 70 (83.3) | 38 (84.4) | 32 (82.1) | |||
| ACPA positive, n (%) | 72 (85.7) | 39 (86.7) | 33 (84.6) | |||
| Symptom duration (months) | 8.0 [3.5–20.0] | 12.0 [4.0–22.0] | 7.0 [3.0–18.0] | |||
| Disease activity | ||||||
| DAS44 | 3.4 (1.2) | 3.2 (1.2) | 3.6 (1.1) | 1.4 (0.9)* | 1.0 (0.6) | 1.9 (0.9)‡ |
| VAS global (mm) | 62.0 [41.5–82.3] | 50.0 [29.5–73.5] | 70.0 [57.0–85.0]† | 12.0 [5.0–42.8] * | 5.0 [1.0–12.5] | 40.0 [13.0–50.0]‡ |
| TJC44ritchie | 7.0 [3.3–10.8] | 5.0 [3.0–10.0] | 7.0 [5.0–11.0] | 1.0 [0.0–2.0] * | 0.0 [0.0–1.0] | 2.0 [1.0–6.0]‡ |
| SJC44ritchie | 6.5 [3.0–13.0] | 7.0 [2.5–13.0] | 6.0 [3.0–12.0] | 0.0 [0.0–2.0] * | 0.0 [0.0–1.0] | 2.0 [0.0–4.0]‡ |
| ESR (mm/hour) | 20.0 [9.0–32.8] | 15.0 [7.0–30.0] | 23.0 [15.0–40.0]† | 7.0 [5.0–12.0] * | 7.0 [3.5–12.0] | 8.0 [5.0–12.0] |
| CRP (mg/l) | 7.7 [3.9–25.8] | 5.5 [3.5–24.0] | 8.3 [4.3–33.0] | 2.0 [1.1–3.6] * | 1.8 [1.1–3.9] | 2.0 [0.9–3.6] |
| Patient Reported Outcomes Measures | ||||||
| RAID pain (0–10) | 7.0 [5.8–8.0] | 7.0 [4.0–8.0] | 7.5 [6.0–8.3] | 2.0 [1.0–4.5] * | 1.0 [0.0–2.0] | 4.0 [2.5–6.0]‡ |
| RAID FDA (0–10) | 6.0 [4.0–8.0] | 5.5 [2.0–8.0] | 7.0 [5.0–8.3]† | 2.0 [0.0–4.5] * | 1.0 [0.0–2.0] | 5.0 [3.0–7.5]‡ |
| RAID fatigue (0–10) | 6.5 [3.0–8.0] | 5.5 [2.0–8.0] | 7.0 [4.8–9.0]† | 4.0 [2.0–7.0] * | 2.0 [0.0–5.8] | 5.0 [3.0–7.5]‡ |
| RAID sleep (0–10) | 7.0 [2.0–8.0] | 7.0 [2.0–8.0] | 6.5 [3.8–8.0] | 2.0 [0.0–6.0] * | 1.0 [0.0–4.0] | 5.0 [2.0–7.0]‡ |
| RAID physical well-being (0–10) | 4.0 [2.0–7.0] | 3.0 [1.3–6.0] | 5.0 [3.0–7.0]† | 3.0 [1.0–5.0] * | 1.0 [0.0–3.0] | 4.0 [2.0–5.0]‡ |
| RAID emotional well-being (0–10) | 5.0 [2.0–7.0] | 5.0 [1.3–6.8] | 6.0 [3.0–8.0] | 2.0 [0.0–5.0] * | 1.0 [0.0–3.0] | 4.0 [2.0–6.0]‡ |
| RAID coping (0–10) | 5.0 [2.0–7.0] | 3.0 [1.3–7.0] | 5.0 [3.0–7.3] | 2.0 [0.0–4.0] * | 0.5 [0.0–2.0] | 3.0 [2.0–5.0]‡ |
| HAQ (0–3) | 0.9 [0.5–1.5] | 0.8 [0.3–1.3] | 1.3 [0.6–0.8]† | 0.2 [0.0–0.6] * | 0.0 [0.0–0.3] | 0.5 [0.1–0.9]‡ |
Numbers are presented as mean (SD) or median [IQR] unless otherwise stated
ACPA anti-citrullinated protein, CRP C-reactive protein, DAS44 disease activity score of 44 joints, ESR erythrocyte sedimentation rate, FDA functional disability assessment, HAQ Health Assessment Questionnaire, IQR interquartile range, l liter, mg milligram, mm millimeter, n number, RAID Rheumatoid Arthritis Impact of Disease questionnaire, RF rheumatoid factor, SD standard deviation, SJC44 swollen joint count of 44 joints, TJC44 tender joint count of 44 joints, VAS visual analogue scale
*Significant improvement (p < 0.05) for the total population, between baseline and 12 weeks after treatment
† Significant difference (p < 0.05) in baseline values between patient in and patient not in self-perceived remission after 12 weeks of treatment
‡ Significant difference (p < 0.05) in week 12 values between patients in and patient not in self-perceived remission after 12 weeks of treatment